EpiVacCorona is developed by the Vector State Research Center of Virology and Biotechnology Credit: Dimitri Houtteman on Unsplash.

Russia has launched the post-registration trials of EpiVacCorona, a Covid-19 vaccine candidate developed by the State Research Center of Virology and Biotechnology, Vector.

The vaccine does not contain the live virus and develops immunity by using artificially synthesised peptides.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In July, the Vector Research Centre got Russian Health Ministry approval to carry out the human trials of the vaccine and the first volunteer received the vaccine shot on 27 July.

Russian Federal Service Oversight of Consumer Protection and Welfare head Anna Popova was quoted by TASS news agency as saying: “We can only stop the spread (of Covid-19) through vaccination.

“On October 13, the Epivaccorona vaccine based on peptide antigens has been registered, right now, the third stage of post-registration trials is underway.”

EpiVacCorona is the second Covid-19 vaccine to receive approval from the Russian authorities.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In August, Russia became the first country to grant regulatory approval to a Covid-19 vaccine when Sputnik V was officially registered ahead of large-scale trials.

Earlier, Russian Deputy Prime Minister Tatyana Golikova had said that she tested EpiVacCorona vaccine herself and no side effects were experienced.

Last week, the Russian Direct Investment Fund (RDIF) and Gamaleya Center announced that a first interim analysis of Phase III trials of the Sputnik V vaccine demonstrated 92% efficacy in Covid-19 patients.

The interim data was based on the double-blind, randomised, placebo-controlled trials. They analysed the efficacy among 16,000 participants who were given the vaccine or placebo 21 days after the first injection.

Sputnik V is the first registered vaccine against the disease created on a human adenoviral vector platform.